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Abstract 
With the move towards more ‘outcome’ and ‘value’-based treatment regimens – increasingly 
tailored for the individual patient – there is growing pressure on healthcare systems and the 
pharmaceutical sector to collaborate and co-develop innovative models of care and medication. This 
paper focuses on the impact disruptive digital technologies may have on the UK Pharma/National 
Health Service (NHS) ecosystem, and is set within the boundaries of treating chronic diseases. A 
comprehensive generic model for designing more ‘connected’ value networks is developed, and 
validated by an expert panel in the specific case of type 2 diabetes.  
An underlying ‘disconnection’ between e-healthcare and pharma value networks, operating as 
independent entities, is demonstrated. Moreover, the extant literature details only simple product-fee 
relationships, without considering the value potential of more digitally connected partnerships. Hence, 
we explore the potential for emerging product-service system (PSS) concepts involving, for example, 
health information exchange mechanisms, interoperability and data analytics, wearable technologies, 
and patient Apps. Scenarios involving more distributed ‘make-to-order’ service models are also 
represented by the model - demonstrating the potential for technologies, such as 3D printing, to 
enable localised and personalised medication manufacture 
Underpinned by the literature on digital/IoT-based business models and PSSs, the conceptual 
model reduces complexity and provides practical guidance on future operating principles and 
protocols to be used in the design and implementation of improved e-healthcare solutions. In turn, this 
enables stakeholders to better understand potential relationships, serviceable aspects, data flows and 
revenue streams. Through use of the model, various disparities in key stakeholder perspectives are 
also captured in this paper. Findings include concerns on the collection and use of patient data, except 
if partnering mechanisms with the NHS were in place, and when devices/services could be provided 
for free. Stakeholder viewpoints expressing a preference to be at the centre of data collection, 
disagreement over data ownership and financial models, and the difficulty in establishing partnerships 
from a wearables technology provider perspective are highlighted.  
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1. Introduction 
As global life expectancy continues to rise, and the prevalence of chronic illness intensifies, the 
current nature of care is becoming unsustainable. Consequently, there is increasing pressure on 
healthcare providers to adopt new models of care and medication to meet the individual needs of a 
growing population (Brach, et al., 2005).  
The world is also becoming more ‘digitalised’. Emerging disruptive technologies have 
impacted customer expectations and human factors in ways never seen before: patient demand is not 
just increasing, its fundamental nature is changing (Jimenez, 2015).  Digital technologies are 
transforming the rules of the global healthcare landscape, making the concepts of personalised 
medicines, treatments and remote healthcare services a distinct reality (Champagne, Leclerc, & Hung, 
2015). However, radical transformation - with respect to healthcare systems and pharmaceutical 
industry structures, processes and technologies - is required to embrace this digital era and address 
the modern issues of growing life expectancy and chronic illness (Taylor, 2015).  Future healthcare 
solutions will require more end-2-end (E2E) collaboration across the value chain, in developing new 
models of care based around improved patient compliance, adherence and ‘personalisation’ 
(Harrington and Srai 2016). Furthermore, Beni (2011) and Ahluwalia, Gimpel, and Varshney (2015) 
highlight the need for studies on medication adherence within the electronic healthcare research 
domain.  
While a value chain has been defined as “the entire production chain from the input of raw 
materials to the output of final product consumed by the end user” (Porter, 1980), in studies of the 
healthcare and pharmaceutical sectors, ‘value network’ terminology is often used, to reflect activities 
being increasingly spread across many specialised firms, (Edwards 2009; Harrington, Philips, and Srai 
2017). In this study, we argue that despite the increased blurring of industry boundaries (Srai, 
Harrington, and Tiwari 2016), pharma value networks and e-healthcare systems remain ‘siloed’, and 
continue to operate largely as independent entities. Indeed, limited attention has been paid to the role 
of the ‘industrial system’ in linking technology developments to final products, and how the design of 
the value network needs to provide the ‘connectivity’ between the two (Harrington and Srai, 2017). 
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Figure 1 illustrates how digital technologies may conceptually connect industrial systems – in this 
case, the digital pharma landscape, the e-healthcare system, and the patient.  
 
                  
 
 
Figure 1. Digital technologies connecting industrial systems – digital pharma and e-healthcare 
(Adapted from Burns 2002; Porter 2005; Srai et al., 2014; Daly et al., 2015; Harrington, Philips, and 
Srai 2017) 
 
 
The pharma/healthcare sector is a challenging environment, regarded as one of the most complex and 
interesting ecosystems to study, and is characterised by numerous stakeholders and regulations 
(Campbell, et al., 2000) Shah 2004; Srai et al. 2015). This research challenges the status quo by 
exploring what impact digital technologies in e-healthcare, coupled with advances (for example) in 
disruptive continuous manufacturing processes within the pharma sector, may enable. In combination, 
these could promote more interconnected, holistic and proactive care models personalised to patients 
and their data. The study is set within the boundaries of chronic disease treatment within the UK 
healthcare system. Human factors are a distinctive challenge in the state funded system as patients 
believe they have the right to the best possible care, provided free at the point of access. Another 
unique feature is that the end customer (individual patient) usually does not understand how the 
product/drug works, nor do they decide on the dosage or specific variety/brand. Hence, the medicine 
supply network is characterised by huge complexity, given its highly customised nature, and the 
unique role of the government who (in the UK) finance the majority of the costs. 
The aim of this paper is to define operating principles and protocols in a variety of healthcare 
contexts where there is a specific focus on service transformation, enabled by a series of emerging 
manufacturing paradigms and novel business model concepts. A conceptual model representing more 
connected value networks that are enabled by emerging protocols, is developed and tested. This 
provides a framework and language for talking about values in the design of e-healthcare systems, 
and allows designers to directly evaluate the success of specific solutions (Bhartiya and Mehrotra, 
2015; Harrington et al., 2016; Midha, Ngafeeson and Ghosh, 2017). Hence, the model simplifies the 
complexities of the entire ecosystem and aims to enable key stakeholders to better understand 
potential relationships, serviceable aspects, data flows and revenue streams, previously unconsidered 
in literature. 
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Future service network configuration options, the ‘touch-point’ processes for better network 
integration, and the data requirements in supporting the effective implementation of a series of service 
strategy scenarios can be assessed. These scenarios include the adoption and use of health IT tools, 
social media, clinical decision support and business intelligence systems that specifically focus on 
extending ‘concepts of operations’ and service ‘outcome’ contracting models to an e-healthcare 
context (Harrington and Srai 2016). For example, for the provision of care and the treatment of 
diabetes — we focus on mobile phone technologies and ‘product-service’ design to develop and test 
more collaborative E2E solutions that better support self-management by patients. The model can 
also capture emerging distributed ‘make-to-order’ service models for pharmaceutical supply—driven 
by digital manufacturing (continuous processing, process analytics) and supply chain concepts, and 
‘activated’ patients (Harrington and Srai 2016).  
Finally, the conceptual model can be used to inform new institutional governance models in e-
healthcare—re-defining the role beyond that of traditional regulatory control and governance tasks, to 
one of being able to facilitate performance ‘outcomes’ (Harrington et al., 2016). It may promote a more 
partnered approach involving patients, e-healthcare system stakeholders, and the pharmaceutical 
sector.  
The paper is structured as follows: Section 2 summarises the key literature to inform the 
development of the conceptual model. Section 3 outlines the mixed methodology used, involving both 
interviews and an online survey, to gather primary data and develop a model. Section 4 presents the 
final conceptual model, and its development based on data collected through interviews and survey 
results. Section 5 presents the conclusions and limitations of the study, in addition to directions for 
future research in this area. 
 
2. Literature Review 
This section reviews the academic literature and summarises concepts involving digital technologies 
and emerging business models. Structured around the following three research themes, these key 
insights inform the development of the conceptual model.  
 
 Technology developments 
 Emerging product-service systems 
 Future (digital) business models 
 
 
2.1. Technology developments 
Manyika, et al. (2013) report that the top four technologies likely to have the most significant impact by 
2025 to be the mobile internet, automation of knowledge work, the IoT and cloud computing. For their 
effective implementation in healthcare, the design and use of technology-enabled systems must reflect 
the needs, lifestyles, and preferences of patients (Dadgar and Joshi, 2017). The academic literature 
relating to digital wearable technologies is also growing (Rodgers, et al., 2015; Taylor, 2014; Wang, et 
al., 2014; Chan, et al., 2012) with multiple applications in the monitoring of cardiovascular, diabetes 
and respiratory diseases. There are also examples in the literature of mobile phone technology use in 
improving health outcomes for chronic disease conditions and the self-management of breast cancer, 
post-hospitalisation HIV and pharmaceutical care (e.g. Sahu, Grover, and Joshi, 2014). While specific 
parameters to monitor are also well documented (Chan, et al., 2012), the extant literature fails short in 
addressing what patients value the most in terms of self-management, and how these preferences are 
designed in (Dadgar and Joshi, 2017). This section briefly summarises technology developments and 
the role of digital technologies and data in bridging the gap between health providers, the 
pharmaceutical industry, and patients. 
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Major technology firms, such as Google and Apple, are now venturing into the chronic disease 
monitoring market. Google partnered with Novartis to develop the ‘Google Lens’ (Barclay, 2014), while 
Apple has partnered with Dexcom on an App to work with the ‘Share2 GCM’ device. The sensor 
(implanted under the skin) transmits data, via a smartphone, to healthcare professionals. It can also 
allow users to easily monitor their condition through real-time graphs and alerts (Neithercott, 2015). 
Other proof of principle concepts explored include the ‘GlucoWatch® biographer – the first minimally 
invasive glucose monitoring watch (Tierney, Tamada, Potts, Jovanovic, & Garg, 2001) – although later 
banned by the FDA (Chan, Estève, Fourniols, Escriba, & Campo, 2012). More recently, the FDA has 
approved two wearable-devices for use in clinical trials. The devices designed by Camntech include 
the ‘MotionWatch 8’ and the ‘PRO-Diary’. These are intended to acquire and analyse movement data, 
and can be pre-loaded with survey questions, enabling users to provide feedback throughout the trial 
(Comstock, 2014). Another recent example is the FDA’s approval of a “smart inhaler” that fuses 
Propeller Health’s respiratory disease management technology with GSK’s dry powder inhaler Ellipta. 
A sensor made by Propeller Health is at the centre of this system, and can attach itself to various 
inhalers to transmit usage information through Bluetooth to a smartphone app. Machine learning then 
helps synthesise this data to help patients and physicians understand where, when, and why patients 
use their inhalers1. 
Digitalisation within healthcare doesn’t just relate to wearable-devices, it is about the 
convergence of multiple technologies (Phillips, Harrington and Srai 2017). Crucially, with a future 
focus on niche and personalised products serving new and multi-faceted markets, updated distribution 
and production methods will be required (Srai & Alinaghian, 2013). A key focus is the IoT, defined 
here as “a manageable set of convergent developments in sensing, identification, communication, 
networking, and informatics devices and systems” (ECIS, 2009). Hence, it is about the E2E network of 
objects and sensors that may produce, receive, and share big data (Calia, 2010), as well as the 
supporting supply chain infrastructure and data analysis required to provide viable care in the future 
(Kang, 2012; Harrington and Srai, 2016).  
The literature relating to the IoT and e-healthcare is considered here in three architectural 
layers, namely the wireless sensor network (WSN), e-Health gateway and the application/back-end 
system (Rahmani, et al., 2015); (Sun, et al., 2012). The WSN integrates various autonomous sensors, 
usually incorporated into wearable technologies, into a network of health data collection. The e-Health 
gateway is concerned with how the associated data is transmitted to an external body (such as 
physicians). The third layer (back-end analysis) is where physicians may access and analyse the 
collected data to enable the provision of remote advice. The literature also details various examples of 
complete e-healthcare solutions (Rahmani, et al., 2015); (Yang, et al., 2014); (Doukas & Maglogiannis, 
2012) and (Dohr, et al., 2010). One example consists of wearable blood pressure sensors, which 
forward the health data of chronically ill/elderly people, through a smartphone, to physicians. Using 
sensors equipped in a smartphone, additional data such as activity may be transmitted 
simultaneously. The physician can then utilise the amalgamated data to monitor health status and 
adherence, offer advice and optimise treatment remotely. This creates a more effective relationship 
between the patient and the physician, and enables relatives to remotely care for patients (Dohr et al., 
2010). 
Finally, Microsoft, Intel and Google are now active in the area of e-health records with their 
ventures: ‘Microsoft Health’, ‘Dossia’ and ‘Google Heath’ respectively. These platforms may enable 
customers to store their health records, pharmacy details and additional data on-line, facilitating 
centralised management and easier access for patients and doctors (Steinbrook, 2008). 
 
2.2. Emerging product-service systems in pharma/healthcare 
The product-service system (PSS) concept (Vandermerwe and Rada (1988) has already been 
comprehensively reviewed in the literature (Baines, et al. 2009). In this study, we focus on a series of 
PSS types proposed, namely ‘Product-oriented’, ‘Use-oriented’ and ‘Result-oriented’ (Neely, 2009). 
                                                 
1 https://www.rdmag.com/article/2016/11/fda-grants-approval-propeller-healths-smart-inhaler 
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This captures a product-service spectrum ranging from customers owning a tangible product with add-
on services (such as maintenance), through to the sharing and leasing of products, and services that 
completely replace product ownership (voicemail services). In addition, we introduce two more recent 
variations from the literature - ‘Integration-oriented’ and ‘Service-oriented’ (Yip, Phaal, & Probert, 
2015).  
The complexity and difficulty of adopting PSSs is also well reported in the literature (Neely 
2007; Ryan et al., 2014). For ‘consumers’ in healthcare (payers and patients), PSSs can mean a shift 
from buying products to buying services and solutions, requiring higher levels of engagement. For 
manufacturers and service providers, the concept results in a greater degree of responsibility across a 
product’s life cycle, (Harrington and Srai 2012). It also needs to involve consumers earlier in both the 
design of the product and system (Mont, 2002) (Dadgar and Joshi, 2017). 
In terms of Pharma, Taylor (2014) reports that the sector has long been considering a 
transition from product-oriented business models to alternatives more closely focused on serving the 
needs of patients. ‘Equally Zeneca’ (now ‘AstraZeneca’) after acquiring ‘Salick Health Care’ in 1997, 
operated a fully integrated cancer and chronic care service in the US, which facilitated performance 
monitoring of their own and competitors’ drugs (Howells, 2000). Another example in healthcare is ‘GE’, 
who have a maintenance based PSS for their CAT and MRI imaging products (More, 2001). The 
rapidly changing landscape in the fields of communications, Internet and social media makes it 
imperative for professionals to better understand the role of Information and Communication 
Technologies and their impact on everyday activities (Apostolakis et al., 2012).  
Despite the fact that the concept holds great potential to address major challenges within 
healthcare , PSSs are relatively unexplored in the literature (Mittermeyer, et al., 2011) with limited 
examples reported (Yip, et al., 2015); (Ryan, et al., 2014); (Velikanov, et al., 2013) (Köbler, et al., 
2009) and (Ajai, et al., 2009). In the context of this study Ajai et al., (2009) detail the design of a 
results-orientated PSS for point-of-care devices, with a case study to collect and transmit health data 
back to healthcare professionals, enabling the provision of remote services (see Figure 2). Blood test 
reminders and external analysis of results are provided as serviceable aspects made possible through 
more of a ‘closed system’. There is also limited literature discussing the potential for a PSS model 
spanning both healthcare and pharmaceutical sectors. While Mittermeyer, et al. (2011) report a 
comprehensive case study, detailing B2C and B2B relationships and product/service components of a 
drug/device combination, it does not contain any reference to wearable devices and IoT, or base any 
serviceable aspects on digitalisation. 
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Figure 2. Schematic of a product-service system for point-of-care devices (Ajai et al. 2009) 
 
2.3. Future (digital) business models 
Digital/IoT-based business models are relatively few, with limited frameworks currently reported in the 
academic literature (Osterwalder and Pigneur, 2010; (Fan & Zhou, 2011) (Sun, et al., 2012) (Dijkman, 
et al., 2015); Chan, 2015. Liu and Jia (2010) present a detailed overview of where IoT could be 
applied, proposing two business model framework variations in a healthcare context. The authors also 
highlight the key actors involved in the drug supply chain and their value interfaces (flow of goods, 
services and finance). Figure 3 illustrates one of the two model variations that focuses on the ‘terminal 
equipment provider’. Both models proposed by Liu and Jia (2010) demonstrate a distinct disconnect 
between the drug manufacturer (pharma) and the patient, with little to no interaction or feedback 
detailed between the two. This was a recurring theme across this literature review, and is also echoed 
in the supply chain literature (Pedroso & Nakano, 2009). Most models primarily concentrate on how 
IoT could help drug manufacturers optimise inventory and supply processes, whilst assisting hospitals 
improve the traceability of drugs. The extant theory does not detail how both pharma and healthcare - 
collecting and sharing data through the IoT - could enable services (such as personalised medication 
and/or remote treatment). In addition, there are no protocols or operating principles detailing how data 
could be collected and transmitted. Moreover, the literature details only a simple product-fee 
relationship between the two industries, without considering the value potential of more digitally 
connected partnerships.  
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Figure 3. Drug supply chain IoT business model – illustrating disconnection between pharma and the 
patient (adapted from Liu and Jia, 2010) 
 
The concept of a digital supply chain has been described as being a smarter supply chain that can 
interact with customers throughout the entire product lifecycle - prioritising flexibility and visibility 
(Chen, Long, and Yan 2004; Butner 2010; Harrington and Srai, 2016). In order to address several 
issues within pharma and healthcare, a large body of literature is starting to emerge on the adoption of 
digital supply chains (Zhou, Chong, & Ngai, 2015); (Narayana, Kumar Pati, & Vrat, 2014). For efficient 
and effective implementation of more digitalised supply chains, the literature principally stresses the 
need for data driven business models to resolve issues of collaboration and coordination between 
players (ibid).  
 
2.4 Research Gap Identification 
Patient-centric healthcare subscribes to the belief that the patient has values that are important in the 
healthcare experience, and in the relationship between those providing care and the patient 
(Puustjarvi and Puustjarvi, 2011). Extending this idea to incorporate the role of digital pharma, the 
research objective of this study may be defined as ‘exploring the potential for a patient centric, 
connected value network, based on digital technologies (continuously collecting and communicating 
patient data), in order to promote ‘personalised’ treatment for a specific patient population.’ 
The primary gaps identified from the academic literature relate to the roles key stakeholders 
may play in the digitalisation of healthcare and in the treatment of chronic illness. There was also little 
evidence on how emerging digital technologies may better integrate the pharma sector with patients 
and healthcare providers, how a more connected system could be structured, or what value this could 
generate for each stakeholder. Similarly, limited literature exists that examines PSSs in the context of 
pharma and none explore how PSSs, combined with the IoT, may influence business models and/or 
value capture. Questions such as: who would pay for the technology; who would own the data 
collected; who could use/share the data; what outcomes could be targeted with the data, are currently 
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unanswered in the literature. Here, understanding current and future configurations is critical when 
exploring the relative attractiveness of potentially disrupting technology interventions in medicine 
manufacturing and healthcare management, and ensuring consistent “like for like” business case 
comparisons (Settanni et al., 2017).  
From a practical perspective, the use of mapping techniques can serve to reveal the main 
interactions and linkages between emerging constructs (Srai 2017). In the case of electronic health 
records - Samhan and Joshi (2017) used mapping techniques to uncover underlying concepts that are 
shaping a series of constructs identified as being critical; costs, benefits, perceived value, perceived 
threat, organisational support, self-efficacy, and system circumvention availability. While limited 
literature has considered both pharma and e-healthcare constructs, in unison, a basic conceptual 
value network for the adoption of e-commerce in pharma has previously been developed (Allee 2000). 
Appendix I illustrates this framework for mapping and clearly articulating the flow of goods, services, 
revenue and knowledge between actors.  
Building on the gaps identified in the literature and the mapping approaches outlined here, 
section 3 now sets out the methodology and process in developing the conceptual model. 
  
3. Methodology 
Figure 4 outlines the development of the conceptual digital value network model. Building on 
the gaps identified in the literature and the mapping approach in Appendix I, a mixed methodology 
involving both interviews and an online survey was employed to gather primary data. Both interview 
and survey methods were selected to gather as broad a range of perspectives within the ecosystem 
as possible. Utilising the two separate sources of data also allowed for better data triangulation and 
increased the validity of findings (Eisenhardt & Graebner, 2007). Interviews were employed to collect 
rich, empirical data and capture the viewpoints of pharma, device manufacturers, the UK’s National 
Health Service (NHS) and academics (Eisenhardt & Graebner, 2007). They were also used to explore 
emergent themes and to better understand the evolution of the ecosystem. Conversely, the survey 
sought to source a broader pool of data, to represent the general public’s views and enable a 
comparison with the interview findings. The methods were employed contemporaneously with findings 
used to dynamically refine/improve the questions, where applicable. 
As outlined in figure 4, the interview process consisted of two stages: The first stage involved 
a pilot to test and refine the structure and wording of the semi-structured interview questions. Stage 2 
involved data collection through in-depth interviews with an expert panel (see Appendix II), to ensure 
appropriateness. This panel was specifically selected to support initial validation of the conceptual 
model in a UK context. Criteria included: individuals who were globally recognised in their domains of 
expertise; were currently in post, or recently held, a senior managerial and/or technical role; had 
relevant experience and knowledge of pharma, healthcare, wearable devices/technology, and/or 
regulatory bodies; had expert knowledge and understanding of chronic disease(s) and respective 
treatment(s) in a UK context; had access to an international network of experts.  
Viewpoints from the expert panel were captured and analysed, using qualitative content 
analysis, to inform the development of the conceptual digital value network model. Qualitative content 
analysis was used to extract relevant information, separating it from the original text, and processing 
only the information that was relevant to inform the development of the conceptual model. This 
specific analysis approach was selected as the research objective of this preliminary study could be 
answered without processing knowledge about the form of statements and position in the text 
(Kohlbacher 2005; Gläser and Laudel, 2013).   
The survey questions were developed to support the interview process, and refine the 
conceptual model. As outlined in figure 4, an online survey was designed and made active over a 
period of two months - from late-June to mid-August 2016. This built on the interviews by capturing 
data to represent the patients’ perspective. It was targeted at the general public and avoided potential 
ethical issues of interviewing patients directly. A process, proposed by Forza (2002), was adopted in 
developing the survey. Initially, a draft set of questions (informed by the literature review) was tested 
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on a population of six people. The survey next went through a process of refinement to ensure it was 
intuitive, was consistent with the respondents’ level of understanding, would take less than 10 minutes 
to complete, and afford valuable data (Forza, 2002).  
The survey was digitalised using the website ‘www.smartsurvey.co.uk’ enabling the use of 
advanced question styles (such as matrix and ranking scales). This reduced the number of questions 
and time required for completion. The structure was as follows; section one (after an introductory 
page) focused on wearable-devices, the second on data collection, the third on business 
models/services, and finally on general demographic details. Question styles were predominantly 
closed with pre-defined options to enable quick data collection and simple quantitative analysis (Forza, 
2002). The option of ‘other’ was included where relevant, along with a comment box for expression of 
alternative or additional views. The introductory page also highlighted the fact data would be collected 
anonymously and for research purposes only. Before official release, the online version was again 
trialled using a larger group of 12 people. This further confirmed intuitiveness, and correct and concise 
wording of questions to ensure key data was captured (Leung, 2001). In total, 122 responses were 
received from the online survey. In reviewing the data, it was found five respondents had not 
completed the form correctly and were consequentially excluded, leaving 117 for analysis. The 
population included roughly an even split of males to females. Five suffered from diabetes and 16 
suffered from other chronic illnesses. The final survey design is included in Appendix III. 
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Figure 4. Methodology and model development: investigative phase exploring key insights derived from the academic literature, supported by data collection 
(interviews and survey), and final expert panel assessment 
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4. Digital Value Networks - Conceptual Model Development  
As industrial systems become more collaborative and service-based, the value network concept is 
increasingly seen as a valuable mapping and modelling technique to represent such complex 
ecosystems (Peppard and Tylander, 2006; Srai et al., 2016; Settanni et al, 2017). Based on the 
process outlined in figure 4, the framework proposed by Allee (2000) was adapted and extended to 
develop a comprehensive model to explore alternative digital value network options.  
Multi-layer analysis is rarely adopted in the literature, but is stressed by Gupta, et al. (2007) as 
vital to adequately understand how organisations operate within industrial ecosystems. The model 
was therefore structured in a multi-layered fashion, detailing both internal and external relationships 
within and between entities, and demonstrating nuances in data flow. The final model presented here 
has been structured around a joint venture (JV) scenario involving the NHS and a wearable 
technology company – see figure 5. As well as key stakeholders such as the NHS, device/technology 
companies and regulators, the model captures various disparities identified from both the 
pharmaceutical sector and patients. The key model developments are detailed first in subsections 4.1-
4.4. How these developments are supported, by the expert panel and survey, are then outlined in the 
data collection discussion section (section 4.5.). 
 
4.1. NHS/Technology Company Joint Venture scenario 
In this digital value network scenario, the JV forms the central data collection and analytics entity. This 
was based on the publics’ preference, expressed through the online survey, for the NHS to collect and 
analyse their data while drawing on the necessary expertise and rapid innovation capability of an 
established technology company. A JV is the favoured approach here as it was emphasised – through 
the expert panel interviews - that the NHS would not be able to move fast enough on its own to 
establish the infrastructure and analytical ability that such a partnership would enable. In this PSS 
scenario, data could be processed within this entity and distributed to healthcare professionals to 
enable the various remote services detailed in figure 5. Data indicating any adverse events could be 
delivered to the Medicines and Healthcare products Regulatory Agency in the UK (MHRA) 2 in order to 
comply with existing (and/or emerging digital) standards. In addition, data could also be shared with 
specific pharma companies, after individual patient consent has been obtained. This data could 
contain condition-specific, medication reaction details and additional information to enable 
stakeholders to ascertain value and effectively provide personalised medication. To address concerns 
expressed by the public in the survey, the data could be anonymised and encrypted, ensuring only the 
NHS/pharmacies could identify patients.  
4.2. Inclusion of Automated Pharmacies 
Automated (online) pharmacies were incorporated into the model to address voiced legislation 
concerns, and to act as an intermediary between the pharma sector, device companies and the 
patient. Patients could automatically receive personalised medicine and wearable devices from said 
companies, in exchange for digital prescriptions (supplied via GPs), without requiring manual 
collection. An example of such a service is already offered free by ‘PillPack’ in the US3. PillPack 
organises and delivers patients’ medications, daily by the dose, and automatically takes care of refills. 
The automated ordering process could be facilitated via a replenishment request, sent from a 
wearable-device, to both pharmacy (PillPack) and the pharma organisation – enabling better sales 
volume forecasting. Scenarios involving re-distributed and continuous drug manufacture have also 
been captured by the model, demonstrating the potential for technologies, such as continuous flow 
                                                 
2 https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency 
3 https://www.pillpack.com 
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and 3D printing, to enable localised and personalised medication manufacture – potentially at the 
pharmacy (EPSRC, 2013; Srai et al, 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Conceptual model - in designing more ‘connected’ value networks  
K
ey
: 
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4.3. Finance Models and Cost Effectiveness/Safety Analysis 
Based on feedback from the expert panel and survey respondents, it is proposed that the supply of 
wearable devices, personalised medication and the majority of remote services be funded by the NHS. 
To justify the required expenses, the cost effectiveness of devices would first need to be calculated by 
the UK’s National Institute for Health and Care Excellence (NICE)4. This independent body could take 
data generated through research studies/trials (completed by university/NHS partnerships) and the 
MHRA, evaluate the value proposal and make the required recommendations to the NHS. It was 
agreed by the expert panel that the devices could offer substantial value by reducing the cost and 
number of chronic-disease related emergencies. In turn, this could both lower the demand on 
GPs/physicians, and reduce patient suffering.  
Based on insights from the survey results, patients would not be paid for their data, but could 
be given the option in their initial GP prescription consultation to opt-out of a data collection scheme. It 
was also suggested by the expert panel that patients could be given a choice of device features (e.g. 
colour, design and functionality), which could in turn encourage correct use/adherence. 
Personalisation and/or increased functionality could be offered for a fee. 
 
4.4. Incorporating Carers 
Patients with chronic conditions make day-to-day decisions about the self-management of their 
illnesses (Ilioudi, Lazakidou, and Tsironi 2010). Carers/family members have been incorporated into 
the model as, depending on the patient’s condition, certain services may be received and delivered via 
these intermediaries. An example of which could be informatics tools, targeted at multiple user groups, 
to support health outcomes and provide greater independence for older patients (Le et al., 2012). The 
digital value network model demonstrates how both patients and carers could receive 
services/warnings simultaneously, potentially enabling carers to continuously monitor patient 
conditions and be their first point of care in emergencies.  
 
4.5. Survey/interview results discussion and implications 
The overarching theme emerging from the analysis was the level of disparity in a series of stakeholder 
viewpoints. This supports previous research on uncertainty and transformational challenges – in terms 
of opportunity areas, technological readiness and a future vision for the pharma/healthcare sector, as 
a whole (Harrington, Phillips, and Srai 2017). Consequentially, when developing the conceptual 
model, numerous challenges and conflicts of interest had to be considered when encompassing the 
social and economic perspectives of key stakeholders (Jeansson, 2013; Harrington et al., 2016; 
Dadgar and Joshi, 2017). Hence, a descriptive analysis on the survey data was performed to gain 
greater understanding of emerging constructs, needs, and values. In turn, this aided the development 
of a common language across the various stakeholders, which directly relates to the proposed model 
and its information flows. Key findings, and links to model development, are now outlined in sections 
4.5.1-4.5.4. 
 
4.5.1. Data Collection and Use 
It is clearly evident that both the NHS and the pharma sector are actively pushing the adoption 
of digital technologies. In the conceptual model (figure 5), the PSS depicts raw patient data being 
collected/sent via a mobile app before entering the JV to be processed. This app may be regarded as 
semi-external to the wearable devices entity - to imply it could be supplied and created via a separate 
wearable device company, or be included as part of the JV. This semi-external structuring is also 
                                                 
4 https://www.nice.org.uk/ 
  17 
intended to indicate that the company providing/maintaining the app would not necessarily have 
access to patient data before it is processed by the JV. 
There was a general acceptance that wearable devices and Apps represent significant value 
opportunities to patients and companies. Numerous examples of the NHS and specific pharma 
organisations looking to partner, or already partnering, with a range of technology companies was also 
discussed.  
The need for pharma and/or the NHS to form partnerships with such companies was 
emphasised, particularly in the short term, to acquire expertise and the ability to innovate rapidly. 
However, the difficulty of establishing the aforementioned partnerships was highlighted from a 
wearables/technology provider perspective. Key barriers identified by the expert panel included 
bureaucracy, lack of available financial backing and the notoriously low acceptance of new, risky 
technology by the NHS as key issues. 
Critically, the majority of parties interviewed expressed their desire to be at the centre of data 
collection. From the NHS perspective, “third parties are not needed, third parties add cost and 
complexity”, hence, healthcare providers would be best suited to provide data-based services. 
Likewise, from the perspective of pharma/wearable device companies, collecting primary data was 
seen to be in their best interests to develop superior drugs/products, improve supply chain design, and 
enable services such as personalised medication. However, there was a clear preference for the NHS 
over the other options by those surveyed. One respondent added: “I don't have much trust in 
pharmaceutical companies, so I wouldn't want them to access my data”. This perception of pharma 
was a common theme observed throughout the survey and interview process (figure 6).  
 
 
Figure 6. Data use preferences 
Based on these insights, the concept of a JV between the NHS and a technology company 
appears to be the most appropiate and viable solution. However, a concern highlighted by the NHS 
with this scenario was the issue of additional clinical responsibility and implications of data collection. 
Interviewees added that “when you are monitoring the uploaded patient data, your duty of care to that 
patient is 24/7”. This would potentially incur additional staff training and emergency response 
requirements to use and act on data correctly - “does the NHS have the capacity to be responsible?” 
This highlighted the need for greater industrial collaboration – partnering with technology companies 
may facilitate more effective data processing and put in place technological solutions to assist the 
NHS in handling such complexities. 
From a pharma sector perspective, it was highlighted that simply gathering disease-specific data 
would not be sufficient - “I can’t see how just the reaction to the drug is enough to get huge value”. 
Additional data, such as medication and activity details, would also be required to enable meaningful 
analysis. Data quality and reliability were also seen as vital for any analysis to be valuable and utilised 
0% 20% 40% 60% 80% 100% 120%
To better manage/treat your condition
To learn more about the condition for the
treatment of the general public
To process your data in order to offer
information/services to other companies
Percentage of Respondents
For which of the following purposes would you be comfortable with the 
named institutions/companies using your data?
The NHS Pharma Companies
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safely. Here, the survey results indicate that a large majority would be comfortable with the NHS 
collecting such data, as summarised in figure 7. However, it was made clear through discussions with 
experienced medical professionals that the NHS would not have the required knowledge or 
infrastructure on its own to extract value, thereby, further justifying the need for increased 
collaboration.  
 
 
Figure 7. Data collection preferences 
 
While data ownership was found to be a topic of uncertainty and disagreement, the general 
consensus was that patients should own their data. It would therefore be the patients’ right to decide 
who could access it, and whether to charge for its collection. It was emphasised that patients are also 
generally protective of their data and are unwilling for it to be shared without permission. The case of 
the ‘care.data scandal’ was cited as precedent (BBC News, 2014)5. 
The majority of people surveyed would be happy to wear a data collection device, with only 
2.5% stating otherwise. In terms of features - comfort, lightweight in nature and non-invasiveness were 
found to be the most critical for such a device. However, despite the majority of survey respondents 
expressing their acceptance of wearable devices both monitoring and automatically administering 
medication, the latter is not recommended and excluded from the model. This is primarily due to 
concerns expressed in interview that this would cause devices to be deemed as ‘class 3’, significantly 
increasing costs and regulatory burden.  
With respect to key outcomes from data collection, respondents ranked improving their own 
conditions through better management/treatment and personalised medicine as the most vital. 
Ensuring anonymity of data was ranked third with respondents highlighting the importance that data 
could not be used by non-NHS organisations to identify them. Interestingly, receiving a fee for their 
data was seen as the least important option (out of 7 options).  
 
4.5.2. Services 
Both the NHS and pharma organisations were interested in establishing new personalised medicine 
ventures and adopting more data-based services. In addition to “providing to the NHS more than just 
                                                 
5 http://www.bbc.co.uk/news/health-26259101 
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drugs”, this could involve consultation to help develop optimum personalised treatment plans for rare 
conditions. 
In the academic literature, education is presented as being critically important, but it is often 
missing from available mobile Apps (Taylor, 2015). Both the NHS and pharma expressed an interest 
in offering remote education services, with the newly developed ‘My COPD’ exemplified. My COPD is 
a free NHS ‘self-management App’, developed by a third-party, which will provide remote instruction 
on taking medication, reminders, and a mechanism to monitor adherence. NHS professionals stressed 
the importance of such Apps to “give the responsibility back to the patients and to support and 
educate them in terms of self-management”. A suggestion from the pharma perspective would be to 
provide a mobile App/digital leaflet, accessed by scanning a unique code on a patient’s medication 
with a smartphone. This could facilitate services, such as easily accessible disease and personalised 
medication information. It was also highlighted that carers and family members are important 
stakeholders to consider as many chronically ill patients would rely on others to deliver the digital 
services. In addition, services focused on carers, such as remote support or alerts if patients were to 
need assistance, was recommended. Figure 8 illustrates that the majority of respondents (95%) would 
be content in receiving remote data-based services from the NHS, as opposed to pharma 
organisations. 
 
 
Figure 8. Remote services preferences 
Furthermore, 55% were willing to pay a reasonable fee. Although this figure was lower for pharma, 
71% of respondents still stated they would accept services from such companies with 35% also being 
prepared to pay (figure 9). Only 29% stated they would not accept free or chargeable services from 
pharma in this particular case. Moreover, it was found the majority of respondents would be 
comfortable with pharma partnering with the NHS to tackle chronic conditions, on the condition that 
they would not be charged for devices or services. Less than 35% would be prepared to pay anything 
to help improve the treatment of their condition. 
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Customised medication
Medication reminders
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(personalised treatment)
Personalised improvement reporting
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appropriate emergency response
Percentage of Respondents
Would you be comfortable receiving any of the following remote services 
from the named institutions/companies, based on your data?
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Figure 9. Fees and services preferences 
Based on these findings, the opportunity for services across the various stakeholders was 
incorporated into the model in a manner that most appropriately addressed the preferences/concerns 
of the public, the NHS and industry. Given the perceived lack of trust expressed by the public (and 
regulatory concerns highlighted) the concept of a digital leaflet/app is the only service proposed to be 
offered directly by pharma organisations to patients. In addition to pharma providing such services for 
personalised instructions and education, technology/wearables companies could also offer equivalent 
services for devices. 
 
 
4.5.3. Finance and Payment Models 
The financing structure, captured by the conceptual model in figure 5, was based on insights from a 
series of stakeholders. Some disparities were identified - one NHS practitioner/academic suggested 
that “if you give someone something for free, they don’t value it”, which would potentially result in 
improper use or damage; another correspondent stated that “you can’t have a system that has such 
inequity of accessibility”, in that only the affluent could afford it.  
From the device developer perspective, the majority of income comes from services and it 
would be infeasible to provide free devices (due to the large initial capital required). Nevertheless, the 
most common view was that patients should not be charged for devices or services (because the 
majority of chronic disease sufferers do not pay for prescriptions due to their age). The general view 
expressed by pharma/NHS was that they would not be willing to pay patients for their data (outside of 
clinical trials) as this could be seen as unethical, particularly in the case of pharma organisations. 
Figure 10 summarises the survey results on finance models, with preferences informing the 
development of the conceptual model.  
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Figure 10. Finance model preferences 
 
Other interview/survey insights supporting the development of the model centred on data being 
collected and services being offered by the NHS/technology company JV. Here respondents indicated 
they would be happy for the NHS to benefit financially from their data, but not the other listed 
organisations (see figure 11). Furthermore, 31% stated they would not be happy for any entity 
(including the NHS) to benefit financially from their data, stressing it should be used purely to improve 
peoples’ health and not for profit.  
 
Figure 11. Finance model preferences 
A key theme highlighted, from the perspective of the NHS, was that of ‘cost effectiveness’. It was 
emphasised that unless there is a clear value proposal for the NHS, then recommendation by NICE for 
incorporation would be unfeasible. Furthermore, research studies/clinical trials partnerships between 
the NHS and universities would be mandatory to test new technologies and provide NICE with data on 
which to base their analyses. These partnerships, along with NICE and MHRA, would have to be 
funded via bodies separate to Clinical Commissioning Groups (CCGs), such as the Medical Research 
Council (MRC) or the National Institute for Health Research (NIHR). 
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  22 
4.5.4. Legislation and Data Security 
A key theme communicated and incorporated into the model was the likely challenge of legislation in 
establishing a digitally connected ecosystem. It was argued that pharmacies may always have a role 
to play in the network due to current laws governing drug prescription/supply. There were conflicting 
views on whether legislative changes could potentially make pharmacies redundant in the future. 
There was also concerns and disparity over regulations that focused on how pharma organisations 
may interact with patients - highlighting direct marketing and inducement as inevitable challenges.  
Data security and confidentiality were recurring themes with all parties mindful of the potentially 
severe consequences of customer data being hacked, historically leading to lawsuits or fines. The 
NHS partnering with a technology company, and having access to their cybersecurity 
knowledge/infrastructure, was therefore seen as a safer option than operating individually when 
collecting patient data. 
 
5. Discussion and Conclusions 
Digital technologies are becoming increasingly more disruptive and are facilitating a new age of e-
healthcare based on remote data collection and analytics. Future e-healthcare solutions will require 
more end-2-end (E2E) collaboration, in developing new models of care based around improved 
patient compliance, medication adherence and ‘personalisation’. As a result, more ‘connectedness’ 
between e-healthcare and digital pharma is required in order to promote future value-based medicines 
and services tailored for both patient populations, and individual patients.  
A digital value network model for designing ‘connected’ value networks was developed, based 
on a framework proposed by Allee (2000), and key insights from the academic literature on digital 
technologies and emerging business models. The conceptual model was then used to explore 
alternative digital value network options and ‘the potential for a patient centric, connected value 
network…for the ‘personalised’ treatment for a specific patient population’ - the research objective of 
this study.  
A mixed methodology involving both interviews and an online survey was employed to gather 
primary data, and to support the development of the conceptual model. Interviews captured the 
viewpoints of pharma organisations, device manufacturers, the UK’s National Health Service (NHS) 
and academics, as well as emergent themes. Conversely, the survey sought to source a broader pool 
of data, and to represent the general public’s views. Set within the boundaries of treating chronic 
diseases, the model was validated by an expert panel in the specific case of type 2 diabetes, building 
on the emerging domain of digital/IoT-based business models in the academic literature. 
The conceptual model demonstrates the potential relationships between the main 
stakeholders identified in the chronic care ecosystem (pharma, the NHS, device/tech companies, 
regulators and patients). It maps the generic relationships between stakeholders (data/revenue 
streams, knowledge flows, goods and serviceable aspects) made conceivable by, for example, the 
adoption of digital technologies and novel manufacturing processes. Application affords a theoretical 
example for the provision of ‘personalised’ treatment for a specific patient population. The model also 
aims to address some of the various disparities identified between stakeholders within the ecosystem. 
The final model presented was structured around a joint venture (JV) scenario involving the NHS and 
a wearable technology company. Future service network configuration options, the ‘touch-point’ 
processes for better network integration, and the data requirements in supporting the effective 
implementation of a series of service strategy scenarios were assessed. These scenarios included the 
adoption and use of health IT tools, social media, clinical decision support and business intelligence 
systems that specifically focus on extending ‘concepts of operations’ and service ‘outcome’ contracting 
models to an e-healthcare context. The model was also used to capture emerging distributed ‘make-
to-order’ service models for pharmaceutical supply—driven by digital manufacturing (continuous 
processing, process analytics) and digital supply chain concepts. 
Bureaucracy, regulations and legislation within the ecosystem were identified as key 
constraints. These, in combination with NHS’s emphasis on cost effectiveness, highlighted the current 
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difficulty for SMEs in entering the market. This raised a requirement for early communication and 
collaboration in establishing a mutually beneficial, connected network with the NHS/MHRA as early as 
possible to understand their requirements (for new connected devices/digital networks) and ensure a 
clear value proposal.  
Contradicting industrial viewpoints on factors, such as which body should be at the centre of 
data collection will also lead to compromises having to be made. For a safe and secure system to 
ensure patients trust, data collected would need to be accurate, reliable and confidential, guaranteeing 
correct analysis and effective services. The responsibilities of ensuring safe infrastructure for 
collection, that sufficient resource would be available to deal with the data, and incentivising patients 
to use devices (correctly) would also be major challenges to overcome.  
The disconnection between pharmaceutical companies and patients, identified in the literature 
review, was evident from the interviews. Currently, patients only provide feedback to pharma 
organisations during clinical trials and, discounting this, there is virtually no communication channels 
between the stakeholders. This was viewed, from the pharma sector perspective, as a great 
opportunity for emerging digital technologies to build more bi-directional relationships, enable the 
provision of remote services, and reduce patient discomfort. In terms of a disconnection/connection 
between pharma organisations and the NHS, the two bodies currently collaborate together relatively 
closely to develop drugs, negotiate acceptable prices, and control supply levels. However, perceived 
issues around competition and having “values and drivers [that] are very different” currently prohibit a 
more integrated relationship. Despite this, it was stressed that “there is a dialogue [with the NHS] to 
see how [pharma] can work together for the benefit of the patient”, which could be facilitated via 
increased data collection/sharing. 
From an academic perspective, the model builds on the literature and provides a novel base 
for additional research. Academics could apply the generic architecture in specific chronic illnesses, 
different healthcare systems and, potentially, other industrial contexts. As part of a future digital food 
research agenda, the model is being applied to assess a series of value propositions on how 
technology and data could facilitate the integration of other ‘systems’, for example, the integration of 
education, food, and social care. For example, the model could be adapted to monitor nutrition and/or 
allergies, enabling customers/carers to control their/their patient’s diets, via personalised health 
advice, and for suppliers to improve the quality of their products.  
The model also has an important role to play, in practice, in the exploration of current and 
future digital scenarios and business models. It can be applied to assess the relative attractiveness of 
potentially disrupting technology interventions in medicine manufacturing and e-healthcare 
management, ensuring consistent “like for like” business case comparisons. From a value creation 
standpoint, the model also has implications for practice as it captures numerous serviceable aspects 
and potential new business models, previously unidentified in literature. It demonstrates its capacity to 
be used as a strategic planning tool, enabling managers to better position their companies for a more 
digital future. The model also helps simplify the inevitable complexity of a digital environment, 
capturing the rigorous regulations, constraints and barriers to entry for those within, or aspiring to 
enter the market. A significant opportunity here to realise the full value of the model would be to 
collaborate and apply the model with specific organisations. Such cross-disciplinary collaboration 
would ideally include academia working with both the NHS and a leading technology company to 
explore the proposed JV detailed in the model. This would facilitate a more in-depth, company specific 
case study to map out an implementation plan for the required data collection and infrastructure.  
A limitation of the study was potential ethical issues being raised by directly interviewing 
patients suffering from chronic disease. As chronic disease sufferers are generally older than the 
majority of the survey’s demographic, only a limited number of respondents suffered from such a 
condition. As a result, the survey findings should be regarded as an insight into the perspective of 
patients in the near future, and not used to dictate how the system should operate at present. Further 
work could look to gain ethical approval, and acquire a more comprehensive understanding of 
patients’ perspectives.  
While the interview sample may be deemed as low, the eight expert panel interviewees 
presented us with interesting insights, opportunities for future research and - critically - access to their 
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individual networks. Future research plans will include further test and refinement of the conceptual 
framework using a greater interview sample so that any future data is more accurately representative 
of the population sample. To further test the robustness of the model, additional research will focus on 
its application in a variety of chronic disease cases, or cell-based therapies where personalised 
treatment is vital - through accessing the international network of experts identified by the expert 
panel. As the study is predominantly focused on human factors, partnering with academics from the 
social sciences in this process may afford deeper insights. It was also suggested the model may be 
better suited to a more privatised market, where adherence could be more easily incentivised, thus, a 
case study of the US healthcare system is planned. We will explore the opportunities for Blockchain as 
a solution for securely sharing medical records, to tackle the issue of counterfeit drugs, or improve the 
productivity of drug development. This could have major implications for UK healthcare infrastructure 
and enable global pharma organisations to drive value and build trust. New governmental standards 
will likely be necessary to control factors such as access to and security of patient, inventory and 
service level data. We also aim to explore future policy implications as a direct result of digitalisation 
across different industries, and the new roles and responsibilities arising for regulators and other key 
stakeholders.  
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Appendix I. Conceptual pharma e-commerce value network (Allee, 2000) 
 
 
 
 
Appendix II. Interviewees and semi-structured interview questions (industry focus) 
Interview Organisation Role Focus 
Pilot Multi-national pharma Senior manager Pharma 
S1-1 
Wearable-devices start-
up 
Lead engineer/ 
director 
Wearables/technology 
S1-2 
Independent pharma 
consultancy 
Director/senior 
consultant 
Pharma/pharmacy 
S1-3 NHS Professor/GP Healthcare 
S1-4 Multi-national pharma Senior manager Pharma supply chain 
S1-5 NHS/university 
Clinical 
researcher/GP 
Healthcare/devices 
Regulation 
S1-6 NHS/university Professor/GP Healthcare 
S1-7 Multi-national pharma Senior manager Pharma/devices 
S1-8 NHS/university 
Professor/senior 
manager/GP 
Healthcare/technology 
S2 Multi-national pharma Senior manager Pharma 
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Pre-Interview Questions: 
Record interview time/date 
1. Confirm they are comfortable with the interview being recorded 
2. Names, welcome etc. 
3. My background 
4. Project overview, key focus areas and aims/objectives 
5. Overview of confidentiality  
 
General Company Information Questions: 
1. Please give a brief overview of yourself: 
a. Current role 
b. Time in role(s) 
c. Industrial experience 
 
2. Please give a brief overview of your company: 
a. Main focus/company type 
b. Key chronic illness related products/services 
 
Problems with Current Industry Questions: 
1. Discuss what you see as the main drivers in the pharmaceutical industry? 
2. What inefficiencies/problems do you see in the industry? 
3. Describe any disconnect you see between pharma and patients? 
4. Describe any disconnect you see between pharma and the NHS?  
5. Do you believe the pharma industry could benefit from these gaps being connected? Please discuss. 
 
Data Gathering and Use Questions: 
Introduce wearable/digital technologies in the treatment of chronic diseases (sweat patch). 
1. Has your company considered the use of wearable-technologies to improve the treatment of chronic 
disease? Why? Discuss what value this could create. 
2. Discuss who you see owning the data collected from a wearable-device? Could this cause legal issues? 
3. Would your company consider purchasing data from patients if they own their data? Why/Why not? 
4. Would your company prefer to collect/process patient data yourselves, or rely on others? Discuss the 
pros/cons of both. 
 
Services/Business Model Based Questions: 
Introduce the concept of PSSs in healthcare/pharma. 
1. Is your company looking to adopt a more services based, patient-centric business model? Give 
details/examples. 
2. Discuss the services your company could offer to patients if you were able to collect data regarding their 
illness. 
3. Discuss the feasibility/key challenges in offering said services from both business and technical 
perspectives. 
4. Would your company be interested in collecting/processing/selling patient data as a service to the NHS? 
What if it was for profit? 
5. Would your company be interested in purchasing processed data from the NHS as services?  
6. Would your company be interested in any of the data collection finance models shown on the hand out? 
Why? 
 
Potential New System Questions: 
Show and talk through the prototype model. 
1. Could you discuss any issues/recommendations you see with the model? Do you agree with the B2B/B2C 
serviceable aspects? 
2. Please discuss the major challenges in order for this type of network to be developed? 
3. What do you see as the best approach going forward to facilitate the connection of healthcare and 
pharmaceutical value chains? 
 
Wrap Up Questions: 
1. Is there anything else you would like to add? 
2. Would you be happy for follow up questions/clarification? 
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Appendix III. On-line survey design 
Page 1. Welcome 
Please answer the following questions from the perspective that you are affected by a chronic illness 
(such as Diabetes). This survey is for research purposes only. The data you provide will be anonymous 
and will not be disclosed to others. 
 
Page 2. Wearable Technology Questions  
Q1. Which of the following features would be essential for a data collection device used to 
monitor your condition? (Please select all that are relevant)  
   Light weight 
   Non-invasive 
   Comfortable to wear 
   Long battery life (>1 day) 
   Waterproof and robust to survive daily activities 
   Non-visible through clothes 
   Stylish design 
   Automatic (i.e. does not require user input to operate) 
   Connect to mobile phone/smart watch to show user data 
   I would not be happy wearing a data collection device 
   
Other (please specify): 
  
 
  
Q2. Please select your preferred style of wearable data collection device:  
   Wearable patch (on skin) 
   Contact lens with incorporated sensing technology 
   Embedded sensor (under skin) wired to external device (glucometer for diabetes) 
   Embedded sensor (under skin) wirelessly communicating data to smart phone/watch 
   I would not be happy wearing a data collecting patch/device 
  
Q3. Would you also be comfortable with the device automatically administering your medication 
(Assuming it was reliable, accurate and painless)?  
   Yes 
   No 
 
Page 3. Data Collection Questions  
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Q4. Which of the following types of data would you be comfortable with the named 
institutions/companies collecting? (Please select all that are relevant)  
 The NHS 
Pharma 
Companies 
Wearable Device 
Manufacturers 
Independent Data 
Collection 
Companies 
Specific condition data 
(i.e. blood glucose data)             
Emergency data (i.e. 
hypoglycaemic event 
data) 
            
Medication compliance 
data             
Other health data (heart 
rate, diet, age, gender 
etc.) 
            
 
Q5. For which of the following purposes would you be comfortable with the named 
institutions/companies using your data? (Please select all that are relevant)  
 The NHS Pharma Companies 
To better manage/treat 
your condition       
To learn more about the 
condition for the treatment 
of the general public 
      
To process your data in 
order to offer 
information/services to 
other companies 
      
  
Q6. Please rank the following outcomes of using a wearable data collection device in order of 
importance (with 1 being the most important):  
The data is anonymised and cannot be used to identify you     
 
The data is only used by companies you are made aware of     
 
To help improve your condition through better management/treatment    
 
The data is used and stored securely     
 
You receive a fee for your data     
 
To help improve your condition through personalised medicine     
 
To gain a better understanding of the condition to help others     
 
 
Page 4. Services Questions  
Q7. Would you be comfortable receiving any of the following remote services from the named 
institutions/companies, based on your data? (Please select all that are relevant)  
 The NHS Pharma Companies 
Customised medication       
Medication dose reminders       
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 The NHS Pharma Companies 
External health data 
analysis and advice 
(personalised treatment) 
      
Personalised improvement 
reporting       
Remote condition 
monitoring and appropriate 
emergency response 
      
  
Q8. On what financial basis would you be happy to receive the previously selected services from 
the named institutions/companies? (Assuming they were reasonably priced and offered more 
effective treatment than the standard)  
 
Yes, I would pay a 
reasonable fee for 
remote services 
No, I would only accept 
free remote services 
No, I would not accept 
remote services 
The NHS          
Pharma Companies          
  
Q9. Would you be comfortable with any of the following companies/institutions benefiting 
financially from your data?  
   The NHS 
   Pharma Companies 
   Wearable Device Manufacturers 
   Independent Data Collection Companies 
   I would not be happy for any company/institution to benefit financially from my data 
  
Q10. If pharma companies and the NHS were to partner in a new initiative to tackle chronic 
conditions, which arrangements would you be comfortable with? (Please select all that are 
relevant)  
   Free wearable device, free services, payment (to you) for data collection 
   Free wearable device, free services, no payment (to you) for data collection 
   Free wearable device, chargeable services, payment (to you) for data collection 
   Free wearable device, chargeable services, no payment (to you) for data collection 
   Chargeable wearable device, free services, payment (to you) for data collection 
   Chargeable wearable device, free services, no payment (to you) for data collection 
   Chargeable wearable device, chargeable services, payment (to you) for data collection 
   Chargeable wearable device, chargeable services, no payment (to you) for data collection 
   I would not be happy with any of these 
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Page 5. Final General Questions  
Q11. Please state the gender you identify as:  
   Male 
   Female 
   Prefer not to say 
  
Q12. Please state your age group:  
   <10 
   10-19 
   20-29 
   30-39 
   40-49 
   50-59 
   60+ 
   Prefer not to say 
  
Q13. Please state which type(s) of chronic Illness you currently have/had: (Please select all that 
are relevant)  
   Type 1 Diabetes 
   Type 2 Diabetes 
   Gestational Diabetes 
   I do not suffer from a chronic condition 
   Prefer not to say 
   
Other (please specify): 
 
  
 
  
Q14. Do you agree with any of the following statements regarding your condition? (Please select 
all that are relevant)  
   It is or was easy for you to forget when to take medication and you would benefit from reminders 
   Medication is or was awkward and/or unpleasant to take 
   Travelling to doctors for check-ups is or was inconvenient 
   You feel you would or would have benefited from more tailored treatment 
   
You would feel more secure knowing health emergencies could be detected and addressed 
immediately 
   You do not or did not take medication for your condition 
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   You have not suffered from a chronic condition 
  
Q15. If there is anything else you would like to add please do so here:  
  
 
 
 
 
 
